
Opinion|Videos|August 22, 2024
Starting CML Treatment: Collaborative Choices for Better Outcomes
Focusing on the initiation of treatment for newly diagnosed patients with CML, Jorge E. Cortes, MD, details important factors to consider when starting treatment and Claire Saxton discusses strategies that optimize communication when considering treatment options.
Advertisement
Episodes in this series

This program was made possible with support from Novartis Pharmaceuticals.
Video content above is prompted by the following questions:
- What are some of the most important considerations when starting treatment for a newly diagnosed patient with CML? How do age, comorbidities, and other considerations factor into the treatment plan?
- Describe your best practices in helping newly diagnosed patients with CML better understand their treatment plan given the complexities involved.
- In your experience, what strategies promote transparent communication around treatment considerations?
- How can patients feel empowered to collaborate with their healthcare team to make an informed decision on the optimal initial treatment?
Advertisement
Related to this article

Hematologic specialists discussed where ciltacabtagene autoleucel fits in the treatment paradigm at first relapse and beyond in multiple myeloma.
!["Patients [with cancer] and physicians would rather have a fixed-duration treatment, if possible," said Julie M. Vose, MD, MBA, at SOHO 2026.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/1cfb57db416943d8f8690afb0bc0d13aa3d90683-400x400.jpg?w=350&fit=crop&auto=format)
"Patients [with cancer] and physicians would rather have a fixed-duration treatment, if possible," said Julie M. Vose, MD, MBA, at SOHO 2026.

Amir T. Fathi, MD, explains which AML subgroups were excluded from PARADIGM and why chemotherapy remains standard for them.
Advertisement
Advertisement
Trending on CancerNetwork
1
Subcutaneous Pembrolizumab Approved in Japan for All Tumor Indications
2
Acting on a HER2 Result and Navigating Access to Therapy
3
The Case for Frontline Zongertinib in HER2-Mutant NSCLC
4
Emerging Endocrine Doublets and Serial ESR1 Testing in HR+/HER2− mBC
5

